Abstract Chimaerins are a family of diacylglycerol-and phorbol ester-regulated GTPase activating proteins (GAPs) for the small G-protein Rac. Extensive evidence indicates that these proteins play important roles in development, axon guidance, metabolism, cell motility, and T cell activation. Four isoforms have been reported to-date, which are products of CHN1 (a1-and a2-chimaerins) and CHN2 (b1-and b2-chimaerins) genes. Although these gene products are assumed to be generated by alternative splicing, bioinformatics analysis of the CHN2 gene revealed that b1-and b2-chimaerins are the products of alternative transcription start sites (TSSs) in different promoter regions. Furthermore, we found an additional TSS in CHN2 gene that leads to a novel product, which we named b3-chimaerin. Expression profile analysis revealed predominantly low levels for the b3-chimaerin transcript, with higher expression levels in epididymis, plasma blood leucocytes, spleen, thymus, as well as various areas of the brain. In addition to the prototypical SH2, C1, and Rac-GAP domains, b3-chimaerin has a unique N-terminal domain. Studies in cells established that b3-chimaerin has Rac-GAP activity and is responsive to phorbol esters. The enhanced responsiveness of b3-chimaerin for phorbol ester-induced translocation relative to b2-chimaerin suggests differential ligand accessibility to the C1 domain.
Introduction
Rac, a small GTPase that belongs to the Rho family, controls numerous cellular functions, including actin cytoskeleton reorganization, motility, and cell cycle progression. Rac activation status is controlled primarily by guanine nucleotide exchange factors (GEFs) that promote GTP loading and thereby activate Rac, and by GTPase activating proteins (GAPs) that inactivate Rac by accelerating GTP hydrolysis. Among the several Rac-GAP families, chimaerins represent a unique class due to their direct regulation by diacylglycerol (DAG), a lipid second messenger that binds to the C1 domain in chimaerins which is highly homologous to C1 domains in protein kinase C (PKC) isozymes. It has been widely recognized that chimaerins play important roles in development, axon guidance, cell migration, and T-cell activation [1] [2] [3] [4] . Early studies determined the existence of four chimaerin isoforms (a1, a2, b1, and b2), reported to be alternative splicing products of the CHN1 (a) and CHN2 (b) genes [5] [6] [7] [8] .
In addition to the C1 domain, all chimaerin isoforms have a C-terminal catalytic Rac-GAP domain. An SH2 domain in the N-terminal region of a2-and b2-chimaerins is possibly involved in interactions with phosphotyrosine Lautaro Zubeldia-Brenner and Alvaro Gutierrez-Uzquiza have contributed equally to this work.
proteins, but its function remains essentially unknown. Binding of DAG or DAG mimetics (such as phorbol esters) to the C1 domain leads to allosteric activation of the protein which, in response to various stimuli, results in deactivation of the Rac GTPase [9] [10] [11] . The crystal structure of b2-chimaerin revealed that the protein is in an autoinhibited state. The N-terminal region of the protein forms a 33 amino acid alpha-helix that rests against the lipid binding site in the C1 domain and occludes the Rac interaction surface in the GAP domain [12] . We have previously identified residues in a2-and b2-chimaerins involved in intramolecular hydrophobic interactions that keep the protein in a ''closed'' conformation. When these residues are mutated, the protein becomes more sensitive to lipidand phorbol ester-induced activation [10, 12] . The fact that chimaerins activity and localization are controlled by different mechanisms as protein-protein or lipid-protein interaction, and phosphorylation [13, 14] strongly suggests that these Rac-GAPs are subject to complex regulatory mechanisms.
It is well established that many eukaryotic genes possess alternative promoters regulating distinct expression patterns, probably because one single transcription start site (TSS) or regulatory region may not always be sufficient to accommodate all the required gene expression regulations (e.g. different tissues, different stages of development). Although alternative TSSs have been reported for many genes, this phenomenon still remains poorly understood. A recent report shows that more than 40 % of developmentally expressed genes in Drosophila melanogaster have at least two alternative promoters generally involved in distinct regulatory programs [15] . The usage of alternative promoters could generate protein variants, differentially regulated 5 0 UTRs, or a combination of both. In yeast, the 5 0 UTR in mRNAs can regulate translation efficiency, and this accounts for large changes in protein expression levels [16] . Regulation of mRNA localization and transport could also depend on 5 0 UTR sequences. At the present time there is no information on whether b-chimaerin isoforms could be generated as a consequence of alternative transcription mechanisms. Here we carried out a thorough analysis of the CHN2 gene, which led us to the identification of a novel bchimaerin isoform, b3-chimaerin, that is the product of an alternative TSS in the CHN2 gene.
Methods

Materials
Cell culture reagents were obtained from Invitrogen (Carlsbad, CA). Reagents for the expression and purification of recombinant glutathione S-transferase (GST) fusion proteins and Gammabind G-Sepharose were purchased from Amersham Biosciences, Inc. (Sunnyvale, CA). Phorbol 12-myristate 13-acetate (PMA) and GF109203X were purchased from LC Laboratories (Woburn, MA).
Cloning of b3-chimaerin and plasmids b3-Chimaerin was amplified by PCR using commercial cDNA from human brain and kidney (PrimerDesign, Southampton, UK) and a Labnet MultiGene TM 96-well gradient thermal cycler. As primers we used 5 0 -ctcgagggatccatgacccagacccacagg (sense) and 5 0 -acgcgtgcggccgcggattagaataaaacgtcttcg (antisense) (Fig. 1c) . The same primers were used to clone the entire b3-chimaerin cDNA from A-172 and U-373 human cell lines.
PCR products were ligated into pCRII using the TA cloning kit (Invitrogen) or pCR2.1-TOPO using the TOPO TA cloning kit (Invitrogen). EcoRI-BamHI or BamHIBamHI fragments were isolated from these plasmids and subcloned into pEGFP-C3 or pEGFP-C1. All constructs were verified by sequencing.
Cell culture and transfections
Cell culture reagents were obtained from Invitrogen (Carlsbad, CA). COS-1 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10 % FBS, 100 U/ml penicillin, and 100 lg/ml streptomycin in a humidified 5 % CO 2 atmosphere at 37°C. Cells in 6-well plates at 50 % confluence were transfected with different mammalian expression vectors (1-2 lg) using polyethylenimine (CELLnTEC, Bern, Switzerland) according to the manufacturer's protocol.
Determination of Rac-GTP levels
Rac-GTP levels were determined using a pull-down assay, as previously reported [17] . Briefly, cells were lysed in a buffer containing 8 lg of GST-PBD domain, 20 mM TrisHCl, pH 7.5, 1 mM dithiothreitol, 5 mM MgCl 2 , 150 mM NaCl, 0.5 % Nonidet P-40, 5 mM glycerophosphate, and protease inhibitors (5 lg/ml 4-(2-aminoethyl) benzenesulfonyl fluoride, 5 lg/ml leupeptin, 5 lg/ml aprotinin and 1 lg/ml pepstatin A). Lysates were centrifuged at 14,0009g (4°C, 10 min) and then incubated with glutathione-Sepharose 4B beads (4°C, 1 h). After extensive washing, the beads were boiled in loading buffer. Samples were resolved in 12 % SDS-polyacrylamide gels and transferred to PVDF membranes for Western blot analysis using an anti-Rac1 antibody (Upstate Biotechnology, Lake Placid, NY). Translocation assays Experiments were carried out as previously described [18] . Briefly, COS-1 cells (2 9 10 5 ) in six-well plates were transfected with pEGFP-b2-chimaerin or pEGFP-b3-chimaerin. After 24 h, cells were treated with different concentrations of PMA for 20 min. To avoid PKC activation by PMA, experiments were performed in the presence of the PKC inhibitor GF109203X (5 lM), added 30 min before and during PMA stimulation. For fractionation assays, cells were harvested into lysis buffer (20 mM TrisHCl, pH 7.5, 5 mM EGTA, and protease inhibitor cocktail for mammalian cell and tissue extract, 1:500, Sigma). Separation of cytosolic (soluble) and particulate fractions was performed by ultracentrifugation [19] . Equal amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis, transferred to PVDF membranes, and immunostained with an anti-GFP antibody (Santa Cruz Biotechnology, Dallas, TX). For fluorescence microscopy visualization, cells were washed with cold PBS, immediately fixed in 4 % PFA and visualized in a Olympus IX71 fluorescence microscope.
Tissue arrays 96-Well TissueScan Human Major Tissue qPCR Array (HMRT102) and the TissueScan Human Brain Tissue qPCR Array (HBRT101) from OriGene (Rockville, MD) were used. Primers for b3-chimaerin were as follows: 5 0 -cattcaggacttacttgcaagccca (sense) and 5 0 -tcttcagcatcgctagt gcagc (antisense) (Fig. 1c) . PCR was performed using the qSTAR SYBR Master Mix kit (OriGene) and an ABI Prism 7300 thermocycler.
Results
Identification of b3-chimaerin
Mammalian b1-and b2-chimaerins have been previously identified as important regulators of the small GTPase Rac. To investigate whether other products of the CHN2 gene might exist, we carried out a screening of EST databases. This led to the identification of a third gene product, which we named b3-chimaerin. b3-Chimaerin was cloned using a PCR approach from two different commercial human cDNAs samples (total brain and kidney) as templates. The PCR products were sequenced, and the full-length b3-chimaerin sequence (Fig. 1a ) was reported to GeneBank (accession ADK47390.1). The b3-chimaerin cDNA was also cloned from A-172 cells (a human glioblastoma cell line) and U-373 cells (a cell line derived from human astrocytoma) (data not shown).
Sequence analysis revealed that b3-chimaerin has a novel N-terminal domain that is encoded by two unique exons located 48 kb upstream from the b2-chimaerin open reading frame (Fig. 1b) . Comparison of protein sequences from b1-chimaerin (NP_001035025.1), b2-chimaerin (NP_004058.1) and b3-chimaerin isoforms revealed in all cases unique N-terminal regions. b1-chimaerin, an isoform only found in testis [5] , is the product of an alternative TSS located on intron 6, *250 kb downstream of the b2-chimaerin TSS. This isoform lacks the SH2 domain and N-terminal a-helix present in b2-chimaerin, which are coded by a cluster of exons 160 kb downstream from the first exon and 80 kb upstream of the b1-chimaerin TSS. On the other hand, b3-chimaerin N-terminal region lacks key residues involved in autoinhibition of b2-chimaerin GAP activity, as also reported for b1-chimaerin [12] , but maintains both SH2 domain and a-helix. The Rac-GAP and C1 domains are encoded by a cluster of exons common to all b-chimaerins. The unique N-terminal region in b3-chimaerin, coded by two exons exclusive of primates, is 91 amino acids long and does not share any sequence identity with other known proteins.
As indicated above, the unique N-terminal domain in b3-chimaerin is encoded by two exons (1a and 2a) located 48 kb upstream from the b2-chimaerin open reading frame, which are followed by exon 2b. Canonical donor sequence of exon 2a binds to the first available acceptor sequence that corresponds with exon 2b. The absence of the canonical acceptor sequence in exon 1b explains why this exon is excluded in b3-chimaerin or other transcripts similar to b3-chimaerin (ENSMBL transcript id: ENST00000539406, ENST00000474070; ENS00000439384). Therefore, b2-and b3-chimaerin cannot be alternative splicing products of the CHN2 gene, supporting the idea that alternate TSSs are responsible for the control of b2-chimaerin and b3-chimaerin expression.
As described previously [5] , the testis-specific b1-chimaerin isoform is the product of an alternative TSS located on intron 6. As shown in Fig. 1b , exon 7b is used as the first exon in b1-chimaerin transcription. This is the seventh exon in b2-chimaerin as a result of a canonical splicing process due to an acceptor sequence located inside the exon which generates a shorter exon (exon 7a) (Fig. 1b) [20] . FirstEF software localized a non-CpG related promoter region 479 bp upstream of the exon 7b start site where a CCAAT box is localized. This CCAAT box in b1-chimaerin is similar to the GGCCAATC box located at nucleotides -519 to -512 in a1-chimaerin. Point-mutation experiments revealed that this sequence is essential for a1-chimaerin expression, and its presence in b1-chimaerin suggests that a similar mechanism to a1-chimaerin may control b1-chimaerin transcription [20] .
Analysis of the CHN2 gene promoters
Although never formally proven, b1-and b2-chimaerins were proposed to be alternative splicing products of the CHN2 gene in chromosome 7 [5, 6, 8] . However, when we carried out bioinformatics analysis of mRNA, ESTs and genomic sequences available in public databases, we found that these b-chimaerin isoforms are products of alternate TSSs regulated by different promoter regions. Sequence comparison between b1-chimaerin (NM_001039936.1) and b2-chimaerin (NM_004067.2) mRNAs, revealed unique 5 0 untranslated regions (UTRs). Alternative TSSs are common features in protein-coding genes and frequently generate alternative N termini [21] . Alternative TSSs usually require distinct promoters that allow RNA polymerase to bind and initiate polymerization of ribonucleotides according to their regulation [21] [22] [23] [24] .
In order to determine if b3-chimaerin is also a product of a new alternative TSS controlled by a new promoter, we used. The encyclopedia of DNA Elements (ENCODE) to identify putative promoter regions flanking the b2-and b3-chimaerin TSSs. This analysis indicated that b2-and b3-chimaerins are the product of alternative TSSs rather than alternative splicing products. As shown in Fig. 2a (track 5) , promoter prediction software FirstEF revealed a CpGrelated promoter in the 5 0 UTR region of both b2-and b3-chimaerins [25] . We also found that both regions showed enrichment for enhancer-and promoted-associated histone marks (H3K4Me1, H3K4Me3, H3ac, H3K27Ac and H3 acetylation), which are usually linked to promoter regions [26] (Fig. 2a, tracks 2, 3, 4 and 9 ). In addition, binding sites for the promoter associated transcription factors USF1/ USF2 and c-Myc located in b2-and b3-chimaerin promoters support our hypothesis (Fig. 2a, track 7, 8 and 9 ) [27, 28] . Moreover, Fig. 2a (track 6) shows that these regions presented high promoter activity in HepG2 human cells and poised state promoter in H1-hESC human cells. Finally, analysis of regulatory potential in these regions using ESPERR, an algorithm that discriminate between regulatory elements and neutral DNA, considered this DNA region as a regulatory element (Fig. 2a, track 11 ) [29] . Using the software methyl primer express (Applied Biosystems, Foster City, CA) we also identified highly dense CpG islands, which are typically associated with promoter regions and transcriptional regulation [30] , in both b2-chimaerin and b3-chimaerin promoter regions (Fig. 2b) . In addition, the Hudson Alpha Methyl-seq consortium reported that these CpG islands are methylated in several human cell lines (Fig. 2a, track 10 ). Taken together, results from CHN2 promoter analysis strongly support the idea that alternative TSSs, rather than alternative splicing, controls the generation of b2-and b3-chimaerins.
Expression of b3-chimaerin
To determine the relative expression of b3-chimaerin in tissues we used a commercial cDNA array (TissueScan Human Major Tissue qPCR Array) and specific b3-primers. Although levels were generally moderate, most tissues expressed b3-chimaerin. The highest levels of mRNA were found in epididymis, plasma blood leucocytes, spleen, and thymus (Fig. 3a) . Given the important function of chimaerins in nervous tissues [1, 31] , we also examined the expression pattern of b3-chimaerin using a human brain cDNA array (Tissue Scan Human Brain Tissue qPCR Array). High b3-chimaerin levels were detected in the pituitary gland, gray cerebellum, white cerebellum and vermis (Fig. 3b) . b3-chimaerin expression was also detected in human cell lines A-172 (glioblastoma) and U-373 (astrocytoma) by RT-PCR (Fig. 3c) and by Western blot using a monoclonal anti-chimaerin antibody (Fig. 3d) . Quantification of chimaerin expression by Western blot showed that b2-chimaerin is 3.1 ± 0.6 times more abundant than b3-chimaerin in A-172 and 1.4 ± 0.3 times more in U-373.
Responsiveness of b3-chimaerin to PMA
In previous studies we established that the C1 domain in b2-chimaerin binds phorbol esters with an affinity similar to C1 domains in PKC isozymes. The C1 domain is responsible for the redistribution of the protein from the cytosol to the plasma membrane where it binds its target Rac [9, 18, 19, 32] . As C1 domains in b2-and b3-b Fig. 2 Analysis of the CHN2 gene promoter. chimaerins are identical, we expected that b3-chimaerin should be responsive to phorbol esters. To address this issue we examined the intracellular redistribution of these chimaerins in response to different concentrations of the phorbol ester PMA using a subcellular fractionation approach. COS-1 cells were transfected with a b3-chimaerin mammalian expression vector and treated with different concentrations of PMA. Cell lysates were prepared, and soluble (cytosolic) and particulate fractions were separated by ultracentrifugation. Western blot analysis revealed that PMA caused significant translocation of b3-chimaerin to the particulate fraction (Fig. 4a) . Densitometric analysis of the immunoreactivity in the soluble fraction allowed us to calculate the EC 50 for PMA-induced b3-chimaerin translocation (180 ± 1 nM, n = 6). In comparison, the EC 50 for PMA-induced translocation of b2-chimaerin was approximately sevenfold higher (1202 ± 1 nM, n = 5). Translocation of b3-chimaerin was also evaluated using fluorescence microscopy. COS-1 cells expressing GFP-b3-chimaerin, or GFP-b2-chimaerin as a control, were treated with vehicle, 0.3 or 30 lM of PMA for 20 min, fixed and visualized for GFP localization. Figure 4b , shows that at 0.3 lM b3-chimaerin accumulates in the perinuclear region. Thus, b3-chimaerin translocates more efficiently than b2-chimaerin in response to activation via the C1 domain.
Analysis of b3-chimaerin Rac-GAP activity Next, we examined the ability of b3-chimaerin to inactivate Rac. COS-1 cells were transfected with mammalian expression vectors for either b2-chimaerin or b3-chimaerin, and Rac-GTP levels were determined using a pull-down assay. Figure 5 shows that, although both b2-chimaerin and b3-chimaerin were able to reduce Rac-GTP levels, b3-chimaerin was more efficient than b2-chimaerin.
Discussion
In this study we identified a novel product of the CHN2 gene, b3-chimaerin. Like b2-chimaerin, b3-chimaerin has the SH2-C1-Rac-GAP domains tandem. The human CHN2 gene possesses at least three alternative TSSs with promoter regions driving the expression of b1-, b2-and b3-chimaerins. b1-Chimaerin, the smallest member of this family, lacking the SH2 domain, was originally described as a splicing variant in the rat testis [5] . However, our analysis showed that this chimaerin isoform is rather the product of an alternative TSS located on intron 6. b2-Chimaerin is the most abundant product of the CHN2 gene. It is highly expressed in the cerebellum and ubiquitously expressed at low levels in various tissues. There are also reports that b2-chimaerin is down-regulated in several cancer types, suggesting a potential role for this protein as a tumor suppressor [8, 17] . Transcription of b2-chimaerin is driven by a promoter region located on intron 2a of the CHN2 gene. b2-chimaerin possesses all three chimaerin domains, an SH2 domain presumably involved in phosphotyrosine binding, a DAG/phorbol ester-responsive C1 domain, and a Rac-specific GAP domain [4, 6] . Additional 5 0 region present in b3-chimaerin mRNA is encoded by two exons located 48 kb upstream of the b2-chimaerin coding sequence. These additional exons generate a unique 5 0 UTR region and an additional N-terminus with no obvious sequence identity to any other protein. The sequence coding for this N-terminal region does not display any known domain or motif, and it was found only in primates, suggesting that it came late in the evolutionary process and that it may be involved in a highly specialized function.
Previous studies have assumed that b1-and b2-chimaerins represent alternative splicing products of the CHN2 gene. Although alternative splicing is responsible for a large fraction of protein variants, it is now recognized that other mechanisms exist, such as the usage of alternative TSSs or alternative polyadenylation signals. These mechanisms produce mRNAs with different 5 0 UTR or 3 0 UTR regions, respectively, which have differential mRNA stability, localization, or translation efficiency [33] . Additionally, these mechanisms could generate protein variants differing in their N-or C-termini. In this paper we show that the different isoforms encoded by the CHN2 gene (b1-, b2-and b3-chimaerin) are not generated by alternative splicing, as suggested previously, but rather through alternative TSSs. Based on this study and our previous observations [13, 34, 35] , and taking into consideration the information provided by the 3-D structure of b2-chimaerin [12] , we postulate that different members of the chimaerin family are subject to distinct mechanisms of control. Crystallographic evidence points to the N-terminal region of b2-chimaerin as a major determinant for autoinhibition. This region forms hydrophobic bonds with residues in the C1 domain that occlude the groove where ligands (DAG and phorbol esters) bind to induce allosteric activation. Specifically, Leu28 in the N-terminal region makes contact with Trp234 and Phe232 in the C1 domain, which prevents the access of ligands. In addition, hydrophobic amino acids in the Rac-GAP domain interact with residues in the C1 domain, thus contributing to the stabilization of the tertiary structure in the autoinhibited conformation. In support of this model, disruption of intramolecular contacts by sitedirected mutagenesis (such as mutation of Leu28 to Ala) reduces the requirement for acidic phospholipids necessary for phorbol ester binding in vitro and sensitizes b2-chimaerin translocation to plasma membrane by phorbol esters and its subsequent association with Rac [12] . Notably, somatic mutations in Leu20 in a2-chimaerin (equivalent to Leu28 in b2-chimaerin), which leads to Rac-GAP hyperactivation, have been found in patients with Duane's retraction syndrome, arguing for a critical role of these internal contacts in keeping the protein in a closed conformation [36] . More importantly, these studies support the concept that the structurally related isoforms a2-and b2-chimaerins are highly regulated proteins and possibly require modifications to destabilize the inactive structure and expose the catalytic Rac-GAP domain [10] . Unlike b2-chimaerin, b1-chimaerin lacks the N-terminal region and therefore is not subject to autoinhibition and allosteric activation. Consistent with this, b1-chimaerin is more sensitive than b2-chimaerin to PMA-induced translocation [32] . Chimaerins are responsible for the reduction in Rac-GTP levels after PMA treatment in the presence of PKC inhibitor GF 109203X [37] . Based on the data presented here, b3-chimaerin resembles b1-chimaerin in its hypersensitivity to PMA-induced translocation. As a potential explanation, b3-chimaerin residues that mask the C1 domain, such as Leu28 in b2-chimaerin, may be displaced or engaged in other interactions within the N-terminus domain, allowing a conformation that is energetically favorable for ligand binding to the C1 domain. Although the N-terminal domain in b3-chimaerin may not be implicated in autoinhibition, we speculate that this region may be involved in some type of protein-protein as recently described for b2-chimaerin N-terminus [38] . In fact, the atypic proline rich motif P(R/H)P(KR) implicated in the interaction with Nck1 is present in b3-chimaerin. More over, the additional N-terminal region present in b3-chimaerin may be subject to post-translational modifications that modulate activation or intracellular localization. Further studies would be required to address this issue.
In summary, here we identified b3-chimaerin as a novel member of the chimaerin family of Rac-GAPs. Our results suggest that individual chimaerin isoforms may be subject to different mechanisms of regulation. It remains to be determined if b3-chimaerin has specialized functions in any given cell type or under different physiopathological conditions.
